$58.40-3.08 (-5.00%)
Pro-Dex, Inc.
Pro-Dex, Inc. in the Healthcare sector is trading at $58.40 with a market capitalization of $208M. Wall Street consensus targets $70.00 (1 analysts), implying a +19.9% move over the next 12 months. The stock is currently 15% below its 52-week high of $68.99, remaining 31.9% above its 200-day moving average. On fundamentals, Piotroski 6/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $19.95M↑ | $18.66M↑ | $18.53M↑ | $17.49M↑ | $17.41M |
| Gross Profit | $6.13M↑ | $5.74M↑ | $5.37M↑ | $3.49M↓ | $5.80M |
| Operating Income | $3.09M↓ | $3.26M↑ | $3.11M↑ | $1.34M↓ | $3.64M |
| Net Income | $3.94M↑ | $2.19M↓ | $4.68M↑ | $1.20M↓ | $3.27M |
Pro-Dex, Inc. designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. It offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers...
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...
Key Insights Significantly high institutional ownership implies Pro-Dex's stock price is sensitive to their trading...
Finding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key...
Long Cast Advisers, an investment management firm, released its third-quarter 2025 investor letter. A copy of the letter can be downloaded here. In the third quarter, the fund’s cumulative net returns improved 4%. The fund returned a cumulative 266% net of fees, or 14% CAGR, since its inception in November 2015 through the quarter-end of […]
Pro-Dex, Inc. ( NASDAQ:PDEX ) shareholders might be concerned after seeing the share price drop 29% in the last...